{
    "ticker": "AIMD",
    "name": "AIM ImmunoTech Inc.",
    "description": "AIM ImmunoTech Inc. is a biotechnology company focused on the research and development of innovative therapies for the treatment of cancer and viral diseases. Founded in 1981 and headquartered in Ocala, Florida, AIM ImmunoTech is dedicated to advancing its lead product candidate, Ampligen, an experimental therapeutic drug designed to enhance the immune response against cancer and viral infections. Ampligen has been studied in various clinical settings, including chronic fatigue syndrome and certain cancers, where it aims to boost the body's natural defense mechanisms. The company also explores additional applications of its proprietary technology platform, aiming to develop new therapies for unmet medical needs. AIM ImmunoTech's commitment to scientific innovation is reflected in its collaborations with academic institutions and clinical research organizations to further investigate the efficacy of its therapies. The company's mission is to provide hope through the development of safe and effective treatments that can significantly improve the quality of life for patients and their families.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Ocala, Florida, USA",
    "founded": "1981",
    "website": "https://www.aimimmunotech.com",
    "ceo": "Thomas K. Equels",
    "social_media": {
        "twitter": "https://twitter.com/AIMImmunoTech",
        "linkedin": "https://www.linkedin.com/company/aim-immunotech/"
    },
    "investor_relations": "https://www.aimimmunotech.com/investors",
    "key_executives": [
        {
            "name": "Thomas K. Equels",
            "position": "CEO"
        },
        {
            "name": "Dr. David L. M. G. B. H. Chang",
            "position": "Chief Science Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Ampligen"
            ]
        }
    ],
    "seo": {
        "meta_title": "AIM ImmunoTech Inc. | Immunotherapy and Biotechnology",
        "meta_description": "Explore AIM ImmunoTech Inc., a leading biotechnology company focused on developing innovative therapies for cancer and viral diseases, including its lead product Ampligen.",
        "keywords": [
            "AIM ImmunoTech",
            "Ampligen",
            "Immunotherapy",
            "Biotechnology",
            "Cancer Treatment",
            "Viral Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is AIM ImmunoTech known for?",
            "answer": "AIM ImmunoTech is known for its research and development of Ampligen, an experimental drug for cancer and viral diseases."
        },
        {
            "question": "Who is the CEO of AIM ImmunoTech?",
            "answer": "Thomas K. Equels is the CEO of AIM ImmunoTech Inc."
        },
        {
            "question": "Where is AIM ImmunoTech headquartered?",
            "answer": "AIM ImmunoTech is headquartered in Ocala, Florida, USA."
        },
        {
            "question": "What is Ampligen?",
            "answer": "Ampligen is AIM ImmunoTech's lead product candidate, designed to enhance the immune response against cancer and viral infections."
        },
        {
            "question": "When was AIM ImmunoTech founded?",
            "answer": "AIM ImmunoTech was founded in 1981."
        }
    ],
    "competitors": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ],
    "related_stocks": [
        "VRTX",
        "REGN",
        "MRNA",
        "ABBV"
    ]
}